Triple-negative breast cancer accounts for approximately 20% of breast cancer cases worldwide. Its hallmark is the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This receptor-negative status precludes the use of hormonal or HER2-targeted treatments, severely limiting therapeutic options. Clinically, TNBC disproportionately affects younger women, exhibits rapid metastatic potential, and is burdened by a high rate of early recurrence and mortality. These aggressive characteristics have positioned TNBC as a critical challenge in oncology.

Given the lack of conventional molecular targets in TNBC, research efforts have expanded beyond the malignant cells to encompass their surrounding environment. The tumour microenvironment comprises a dynamic consortium of connective tissue, immune cells, fibroblasts, extracellular matrix components, and vasculature. This environment can paradoxically either impede or foster tumorigenesis, suggesting that its molecular interplay may hold keys to combating the disease.

In an innovative study published in Current Drug Therapy, a multidisciplinary team at the HSE Faculty of Biology and Biotechnology dissected the gene expression profiles of both TNBC tumour cells and their microenvironment components. By correlating these molecular data with extensive patient clinical records, they identified critical regulatory pathways influencing tumour aggressiveness and patient outcomes. Central to their discovery is the insulin-like growth factor 2 (IGF2), a well-known signalling protein implicated in tissue growth and repair, but hijacked in cancer to fuel unregulated proliferation.

Contrary to conventional assumptions that the tumour cells produce the essential growth-supporting factors, this study found that fibroblasts—connective tissue cells resident within the tumour microenvironment—are the predominant source of IGF2 in TNBC. These fibroblasts, normally maintaining tissue architecture and homeostasis, seem to switch roles under the pathological state, becoming facilitators of cancer progression by secreting IGF2, effectively “fueling the fire” of tumour expansion.

Adjacent to this growth-promoting mechanism, the tumour possesses an intrinsic regulatory system aimed at tempering unchecked development. This restraint is mediated by the insulin-like growth factor binding protein 6 (IGFBP6), a molecular “trap” that binds IGF2, preventing it from excessive activation of tumour cells. Intriguingly, the researchers observed that both tumour and microenvironmental cells produce IGFBP6 as a counterbalance to growth stimuli, suggesting a finely tuned equilibrium under normal conditions.

The study’s clinical analysis revealed a troubling link between diminished IGFBP6 expression and heightened infiltration of macrophages within tumours. Macrophages, pivotal immune cells tasked with host defense, can undergo functional reprogramming in cancer to adopt tumor-supportive roles. This reprogramming fosters a pro-tumoral milieu, promoting angiogenesis, matrix remodeling, and immune suppression, factors collectively contributing to accelerated disease recurrence and poor prognosis in affected patients.

These findings carry immediate translational significance. Measuring IGFBP6 levels in tumour biopsies could serve as a prognostic biomarker, enabling clinicians to stratify patients by recurrence risk more accurately. High-risk individuals with low IGFBP6 expression and macrophage-enriched tumours might benefit from intensified surveillance and tailored therapeutic regimens, potentially improving survival outcomes.

Looking forward, the elucidation of this tumour microenvironment axis opens exciting prospects for the development of novel treatments. Current chemotherapeutic strategies targeting rapidly dividing cancer cells often fall short against TNBC’s resilience. Redirecting therapeutic focus to the supportive fibroblasts and immune components within the microenvironment offers a promising paradigm shift. For instance, elevating IGFBP6 levels pharmacologically or inhibiting IGF2 production in fibroblasts could undermine the tumour’s growth advantage, effectively “starving” cancer cells of their supportive niche.

Maxim Shkurnikov, leading the research at HSE’s Laboratory for Research on Molecular Mechanisms of Longevity, emphasizes this strategic reorientation: “Conventional chemotherapy primarily targets rapidly dividing cells, and in triple-negative breast cancer this is often insufficient. We propose shifting the focus to the tumour microenvironment and targeting the cells that support tumour growth. By modulating IGFBP6 and IGF2 dynamics, we hope to develop therapies that significantly reduce the risk of rapid recurrence.”

This research underscores the critical importance of the tumour microenvironment in dictating cancer progression and recurrence, particularly in TNBC, where options remain limited. It aligns with a growing body of evidence suggesting that addressing not only the malignant cells but also the surrounding stromal and immune components is essential for durable therapeutic success.

Moreover, this discovery may have implications beyond TNBC, offering insights into other malignancies where the IGF axis and immune microenvironment interplay governs tumour behavior. The identification of biomarkers like IGFBP6 and the delineation of fibroblast-derived IGF2 in cancer progression herald a new wave of personalized oncology approaches grounded in microenvironmental biology.

In summary, the HSE University study marks a significant advance in cancer biology, highlighting that the aggressive nature of triple-negative breast cancer is not solely an intrinsic feature of tumour cells but critically influenced by their microenvironment. By targeting these auxiliary cells and their molecular signals, there lies an opportunity to outmaneuver this formidable disease and improve outcomes for patients currently facing limited options.

Subject of Research: Molecular mechanisms and tumour microenvironment in triple-negative breast cancer

Article Title: IGFBP6 Expression Correlates with Macrophage Presence in Triple-Negative Breast Cancer Tumors

News Publication Date: 2 January 2026

Web References:
https://doi.org/10.2174/0115748855416908251120055038

References:
HSE University research team, Current Drug Therapy, 2026

Keywords:
Triple-negative breast cancer, tumour microenvironment, IGF2, IGFBP6, fibroblasts, macrophages, cancer recurrence, molecular oncology, tumour progression, targeted therapy, immune cells, cancer biomarkers

Sphingolipids, a class of lipids with significant structural and signaling roles in cell membranes, have been associated with various cellular functions, including cell growth, apoptosis, and inflammation. Li and colleagues delve deep into understanding how these molecules are not only essential for cellular architecture but are also intricately linked to the molecular pathways that drive TNBC. This dual role of sphingolipids makes them an enticing focus for therapeutic interventions aimed at disrupting the cancer’s survival mechanisms.

The research utilized advanced transcriptomic profiling techniques to dissect the diverse gene expression patterns that characterize TNBC. By correlating these patterns with sphingolipid metabolic pathways, the team established a clear connection between the metabolic fluctuations and changes in gene expression. Notably, they discovered that despite the diversity in transcriptomic profiles among TNBC tumors, sphingolipid metabolism remained relatively consistent, indicating its vital role in the cancer’s biology and adaptability.

One striking finding of the study highlights how various sphingolipids, particularly sphingosine-1-phosphate (S1P) and ceramides, have the potential to modulate tumor aggression and response to treatment. Elevated levels of S1P were linked to enhanced tumor cell survival and proliferation, suggesting a critical coupling between metabolic pathways and the oncogenic behavior of TNBC. Conversely, ceramide levels were associated with pro-apoptotic signals, shining a light on their beneficial role in potentially counteracting tumor growth.

The study’s insights extend beyond the laboratory, emphasizing the translational potential of targeting sphingolipid metabolism in TNBC. The researchers suggest that pharmacological agents designed to modulate sphingolipid levels could provide a therapeutic edge in managing this difficult-to-treat cancer. Existing drugs that influence sphingolipid pathways, either by enhancing ceramide accumulation or inhibiting S1P signaling, could be repurposed or effectively combined with current therapies to improve treatment outcomes.

Furthermore, the implications of conserved sphingolipid metabolism as a prognostic biomarker in TNBC could revolutionize patient management strategies. By leveraging this metabolic profile, clinicians could gain invaluable insights into tumor behavior, leading to more personalized and effective treatment plans tailored to the metabolic realities of individual tumors. This could ultimately improve survival rates and quality of life for patients afflicted with this formidable disease.

In addition to exploring therapeutic avenues, the researchers call for a broader understanding of how sphingolipid metabolism might interact with other metabolic pathways within cancer cells. They propose that multi-omics approaches, integrating metabolomics, transcriptomics, and proteomics, could elucidate the complex interplay between these pathways, offering a deeper understanding of cancer biology.

The potential of sphingolipid metabolism in the field of cancer research expands beyond TNBC. As the cancer research community increasingly focuses on metabolic vulnerabilities, the findings of this study could be applicable to other cancer types showing similar metabolic characteristics. This paves the way for a future where targeting lipid metabolism could become a cornerstone of oncological therapies across diverse malignancies.

As oncologists and researchers digest these insights, a foundational question arises: can we harness the knowledge of sphingolipid metabolism to counter the therapeutic resistance that frequently plagues TNBC? The answer may lie in developing a new class of therapeutic agents specifically designed to rewire the metabolic programming of TNBC cells, ultimately leading to enhanced susceptibility to conventional treatments like chemotherapy.

In light of the study’s implications, it is crucial for future research to investigate the dynamics of sphingolipid metabolism within the tumor microenvironment. Understanding how tumor-associated immune cells might influence or be influenced by these metabolic pathways could clarify the overall role of sphingolipids in tumor progression and response to therapy.

In summary, the study conducted by Li and colleagues unveils a significant intersection between sphingolipid metabolism and gene expression diversity in triple-negative breast cancer. By highlighting conserved metabolic pathways as potential therapeutic and prognostic targets, the research elucidates a promising direction in the quest for effective treatments against one of the most challenging forms of breast cancer. As we look ahead, the ability to manipulate sphingolipid metabolism could herald a new era in personalized oncology, providing hope to millions of women worldwide battling this aggressive disease.

Building upon these findings, continued investigation and clinical trials will be crucial in determining the safety and efficacy of manipulating sphingolipid pathways in cancer treatment. The potential for creating novel therapeutic strategies remains ripe, inviting researchers and clinicians alike to explore this promising frontier in cancer research.

The collaborative nature of this research also exemplifies the importance of interdisciplinary approaches in understanding complex diseases like cancer. The combination of molecular biology, genomics, and clinical insights can catalyze the development of innovative treatments, emphasizing the need for continued collaboration across various scientific domains.

As the landscape of cancer treatment evolves, studies such as this one serve as foundational pillars, guiding future research endeavors and therapeutic strategies. The journey towards unlocking the full potential of sphingolipid metabolism in cancer therapy is just beginning, promising a transformation in how we approach and manage triple-negative breast cancer.

In conclusion, the exploration of conserved sphingolipid metabolism offers a fresh perspective on the underlying mechanisms driving triple-negative breast cancer. By bridging metabolic research with clinical applications, this study not only paves the way for new therapeutic strategies but also enhances our understanding of cancer biology at a fundamental level.

Subject of Research: Sphingolipid metabolism in triple-negative breast cancer

Article Title: Conserved sphingolipid metabolism under transcriptomic diversity: a prognostic and therapeutic target in triple-negative breast cancer

Article References:

Li, J., Chen, R., Wang, X. et al. Conserved sphingolipid metabolism under transcriptomic diversity: a prognostic and therapeutic target in triple-negative breast cancer.
J Transl Med 23, 1217 (2025). https://doi.org/10.1186/s12967-025-07264-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07264-x

Keywords: Triple-negative breast cancer, sphingolipid metabolism, ceramides, sphingosine-1-phosphate, transcriptomics, targeted therapy, cancer biology, personalized oncology.